Neurocrine presents analyses from Phase 4 study with tardive dyskinesia

Neurocrine (NBIX) Biosciences announced the presentation of new analyses from a Phase 4 randomized withdrawal study showing patients with tardive dyskinesia who received continued treatment with INGREZZA, or valbenazine, capsules reported improvements across functional and health-related quality of life measures. These findings complement recently announced patient-reported outcome data from the Phase 4 KINECT-PRO study of INGREZZA, which was the first of its kind to specifically measure and report clinically meaningful improvements in the impact of tardive dyskinesia. The analyses were presented at the 2025 International Society for Pharmacoeconomics and Outcomes Research (ISPOR) Conference in Montreal, Canada. The analyses were conducted using data from 127 patients who participated in a Phase 4, double-blind, placebo-controlled, randomized withdrawal study. Patients received up to 80 mg of INGREZZA for eight weeks, after which they were randomized to either continue INGREZZA or receive placebo for an additional eight weeks. Health-related quality of life was measured using the EuroQol 5-Dimension 5-Level, which includes five dimensions of health status. A utility index, ranging from -0.573 to 1.0, and visual analog scale (EQ-VAS), ranging from 0 to 100, were also reported with higher scores indicating better health status.